- Home
- RDZN vs ACET Comparison
RDZN vs ACET Comparison
Compare RDZN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- ACET
- Stock Information
- Founded
- RDZN 2015
- ACET 1947
- Country
- RDZN United States
- ACET United States
- Employees
- RDZN N/A
- ACET N/A
- Industry
- RDZN Blank Checks
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- RDZN Finance
- ACET Health Care
- Exchange
- RDZN Nasdaq
- ACET Nasdaq
- Market Cap
- RDZN 86.1M
- ACET 70.3M
- IPO Year
- RDZN N/A
- ACET N/A
- Fundamental
- Price
- RDZN $1.16
- ACET $0.67
- Analyst Decision
- RDZN Strong Buy
- ACET Buy
- Analyst Count
- RDZN 2
- ACET 6
- Target Price
- RDZN $5.00
- ACET $6.00
- AVG Volume (30 Days)
- RDZN 178.0K
- ACET 312.0K
- Earning Date
- RDZN 02-12-2025
- ACET 03-06-2025
- Dividend Yield
- RDZN N/A
- ACET N/A
- EPS Growth
- RDZN N/A
- ACET N/A
- EPS
- RDZN N/A
- ACET N/A
- Revenue
- RDZN $42,893,256.00
- ACET N/A
- Revenue This Year
- RDZN $4.52
- ACET N/A
- Revenue Next Year
- RDZN $53.72
- ACET N/A
- P/E Ratio
- RDZN N/A
- ACET N/A
- Revenue Growth
- RDZN 2.79
- ACET N/A
- 52 Week Low
- RDZN $0.71
- ACET $0.67
- 52 Week High
- RDZN $6.67
- ACET $2.40
- Technical
- Relative Strength Index (RSI)
- RDZN 51.69
- ACET 32.94
- Support Level
- RDZN $0.96
- ACET $0.74
- Resistance Level
- RDZN $1.38
- ACET $0.91
- Average True Range (ATR)
- RDZN 0.13
- ACET 0.06
- MACD
- RDZN 0.03
- ACET -0.01
- Stochastic Oscillator
- RDZN 47.62
- ACET 0.36
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.